Founder, Chairman
Current-DAKOTA Life Sciences is a leading anti-infectives private pharmaceutical Company with award-winning products designed to provide the highest efficacy for global patients at high risk of suffering from dangerous microbial and fungal infections. Dakota Life Sciences, Inc., was established in 2010, headquartered in Sioux Falls, SD, and recently expanded its operations with a New York City office and West Coast operations. -The Company launched its first funding rounds as a private placement Reg D Company in late 2011 and early 2013, with the PPMs marketed to accredited investors and institutions. In January, 2014, the company’s legal entity (Thru Pharma, LLC) acquired controlling interest in a public shell company, Arax Holdings, Inc. (“ARAT”), listed on the OTCQB public exchange. Arax Holdings Corporation is a fully reporting, DTC eligible, company. Since that acquisition, various PIPE investments occurred with accredited investors. -The initial product launch of 2016 will be the Company’s FDA-regulated OTC patented ThinNail® brand anti-fungal nail product. The Company will continue to seek transformative technologies that better enable new uses of old antifungal formulations through improved delivery or formulation technology. -DAKOTA Life Sciences was founded based on its topical penetrating technology for drug delivery. That technology, referred to as Site Specific Penetration Technology (SSPT™), has been nationally acclaimed and has received multiple prestigious awards. In 2011-2015, the Company engaged in extensive laboratory and clinical testing of this drug delivery technology. There is currently a significant unmet demand for this product that the Company intends to satisfy in 2016 and beyond. The Company expects to develop and acquire breakthrough technologies in related areas of improved antibiotic deliveries, including systemically delivered medications.
